argenx SE (NASDAQ:ARGX) Shares Acquired by Quadrant Capital Group LLC

Quadrant Capital Group LLC lifted its holdings in shares of argenx SE (NASDAQ:ARGX) by 8.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 979 shares of the company’s stock after buying an additional 74 shares during the quarter. Quadrant Capital Group LLC’s holdings in argenx were worth $382,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. FMR LLC raised its stake in shares of argenx by 0.5% during the 1st quarter. FMR LLC now owns 5,233,498 shares of the company’s stock worth $1,949,897,000 after buying an additional 24,329 shares during the period. Artisan Partners Limited Partnership increased its position in shares of argenx by 15.9% during the first quarter. Artisan Partners Limited Partnership now owns 3,032,228 shares of the company’s stock worth $1,129,748,000 after purchasing an additional 416,813 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of argenx by 1.7% during the first quarter. Avoro Capital Advisors LLC now owns 1,287,500 shares of the company’s stock worth $479,697,000 after purchasing an additional 21,945 shares in the last quarter. Jennison Associates LLC increased its position in shares of argenx by 0.5% during the second quarter. Jennison Associates LLC now owns 1,143,378 shares of the company’s stock worth $445,609,000 after purchasing an additional 5,412 shares in the last quarter. Finally, Capital World Investors increased its position in shares of argenx by 12.0% during the first quarter. Capital World Investors now owns 739,392 shares of the company’s stock worth $233,138,000 after purchasing an additional 79,119 shares in the last quarter. 52.77% of the stock is owned by institutional investors and hedge funds.

argenx Stock Up 0.9 %

Shares of argenx stock opened at $489.77 on Friday. The business’s fifty day simple moving average is $493.30 and its 200-day simple moving average is $460.93. argenx SE has a 52 week low of $333.07 and a 52 week high of $550.76. The firm has a market cap of $28.94 billion, a PE ratio of -117.73 and a beta of 0.79.

argenx (NASDAQ:ARGX) last posted its earnings results on Tuesday, October 31st. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.23. argenx had a negative return on equity of 12.40% and a negative net margin of 22.70%. The firm had revenue of $339.84 million for the quarter, compared to analyst estimates of $310.06 million. During the same quarter in the prior year, the company earned ($4.26) EPS. As a group, equities analysts expect that argenx SE will post -4.76 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on ARGX. Truist Financial reiterated a “buy” rating and set a $570.00 price target on shares of argenx in a research report on Wednesday, November 1st. UBS Group cut argenx from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $480.00 to $570.00 in a research report on Monday, July 24th. HC Wainwright reiterated a “buy” rating and set a $595.00 price target on shares of argenx in a research report on Monday, September 18th. Piper Sandler upped their target price on argenx from $595.00 to $600.00 and gave the company an “overweight” rating in a report on Thursday, August 31st. Finally, Guggenheim upped their target price on argenx from $545.00 to $590.00 and gave the company a “buy” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $542.25.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.